JP2011508765A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011508765A5 JP2011508765A5 JP2010541094A JP2010541094A JP2011508765A5 JP 2011508765 A5 JP2011508765 A5 JP 2011508765A5 JP 2010541094 A JP2010541094 A JP 2010541094A JP 2010541094 A JP2010541094 A JP 2010541094A JP 2011508765 A5 JP2011508765 A5 JP 2011508765A5
- Authority
- JP
- Japan
- Prior art keywords
- disorder
- thcv
- cbd
- drug
- antipsychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 18
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims 12
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims 12
- 208000028017 Psychotic disease Diseases 0.000 claims 12
- 229940079593 drug Drugs 0.000 claims 12
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 10
- 229940076279 serotonin Drugs 0.000 claims 7
- 239000003381 stabilizer Substances 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 5
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- 230000000561 anti-psychotic effect Effects 0.000 claims 4
- 229940127236 atypical antipsychotics Drugs 0.000 claims 4
- 208000027099 Paranoid disease Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 230000000698 schizophrenic effect Effects 0.000 claims 3
- CDONPRYEWWPREK-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-1h-quinolin-2-one Chemical group ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)C=CC4=CC=3)CC2)=C1Cl CDONPRYEWWPREK-UHFFFAOYSA-N 0.000 claims 2
- 206010033864 Paranoia Diseases 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 239000000164 antipsychotic agent Substances 0.000 claims 2
- 229960004372 aripiprazole Drugs 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 229940088679 drug related substance Drugs 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000022821 personality disease Diseases 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims 1
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims 1
- UDQMXYJSNNCRAS-UHFFFAOYSA-N 2,3-dichlorophenylpiperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1Cl UDQMXYJSNNCRAS-UHFFFAOYSA-N 0.000 claims 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 1
- JLLAHJYNQOJXOM-UHFFFAOYSA-N 4-[(2-oxo-3,4-dihydro-1h-quinolin-7-yl)oxy]butanoic acid Chemical compound C1CC(=O)NC2=CC(OCCCC(=O)O)=CC=C21 JLLAHJYNQOJXOM-UHFFFAOYSA-N 0.000 claims 1
- YZIVLADPQQPFLO-UHFFFAOYSA-N 7-[4-[4-(2,3-dichloro-4-hydroxyphenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1h-quinolin-2-one Chemical compound ClC1=C(Cl)C(O)=CC=C1N1CCN(CCCCOC=2C=C3NC(=O)CCC3=CC=2)CC1 YZIVLADPQQPFLO-UHFFFAOYSA-N 0.000 claims 1
- DEZQYWLMDCXTQP-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-4-hydroxy-3,4-dihydro-1h-quinolin-2-one Chemical compound C=1C=C2C(O)CC(=O)NC2=CC=1OCCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl DEZQYWLMDCXTQP-UHFFFAOYSA-N 0.000 claims 1
- 208000009132 Catalepsy Diseases 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- HEJPDCHYELODAJ-DYXRGMLLSA-N O[C@@H]1[C@@H](O)[C@H](Oc2ccc(N3CCN(CCCCOc4ccc5CCC(=O)Nc5c4)CC3)c(Cl)c2Cl)O[C@@H]([C@H]1O)C(O)=O Chemical compound O[C@@H]1[C@@H](O)[C@H](Oc2ccc(N3CCN(CCCCOc4ccc5CCC(=O)Nc5c4)CC3)c(Cl)c2Cl)O[C@@H]([C@H]1O)C(O)=O HEJPDCHYELODAJ-DYXRGMLLSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 101100268917 Oryctolagus cuniculus ACOX2 gene Proteins 0.000 claims 1
- 208000019568 Shared Paranoid disease Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- UCONUSSAWGCZMV-UHFFFAOYSA-N Tetrahydro-cannabinol-carbonsaeure Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCCCC)C(C(O)=O)=C2O UCONUSSAWGCZMV-UHFFFAOYSA-N 0.000 claims 1
- 206010047853 Waxy flexibility Diseases 0.000 claims 1
- XGSPNQWLRVBZIN-UHFFFAOYSA-N [2,3-dichloro-4-[4-[4-[(2-oxo-3,4-dihydro-1H-quinolin-7-yl)oxy]butyl]piperazin-1-yl]phenyl] hydrogen sulfate Chemical compound ClC1=C(Cl)C(OS(=O)(=O)O)=CC=C1N1CCN(CCCCOC=2C=C3NC(=O)CCC3=CC=2)CC1 XGSPNQWLRVBZIN-UHFFFAOYSA-N 0.000 claims 1
- 229960003036 amisulpride Drugs 0.000 claims 1
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims 1
- 229960005245 asenapine Drugs 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 229960005123 cariprazine Drugs 0.000 claims 1
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 claims 1
- 229960004170 clozapine Drugs 0.000 claims 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 229960003162 iloperidone Drugs 0.000 claims 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229960005017 olanzapine Drugs 0.000 claims 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 1
- 229960001057 paliperidone Drugs 0.000 claims 1
- 208000024817 paranoid personality disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000419 plant extract Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229960004431 quetiapine Drugs 0.000 claims 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 1
- 229960001534 risperidone Drugs 0.000 claims 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 1
- 229960004940 sulpiride Drugs 0.000 claims 1
- 229960000607 ziprasidone Drugs 0.000 claims 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0800390A GB2456183A (en) | 2008-01-04 | 2008-01-04 | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
| GB0800390.7 | 2008-01-04 | ||
| PCT/GB2008/004217 WO2009087351A1 (en) | 2008-01-04 | 2008-12-17 | Use of cannabinoids in combination with an anti-psychotic medicament |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011508765A JP2011508765A (ja) | 2011-03-17 |
| JP2011508765A5 true JP2011508765A5 (cg-RX-API-DMAC7.html) | 2012-02-02 |
| JP5409650B2 JP5409650B2 (ja) | 2014-02-05 |
Family
ID=39144704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541094A Active JP5409650B2 (ja) | 2008-01-04 | 2008-12-17 | 抗精神病薬と組み合わせたカンナビノイドの使用 |
Country Status (25)
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| GB2377218A (en) * | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| US9168278B2 (en) | 2004-11-16 | 2015-10-27 | Gw Pharma Limited | Use for cannabinoid |
| GB2459637B (en) * | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
| GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
| GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| EP2551255B1 (en) * | 2010-03-26 | 2017-11-08 | Vivacell Biotechnology España, S.L | Cannabinoid quinone derivatives |
| TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Ｇｗ伐瑪有限公司 | 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途 |
| US8445034B1 (en) | 2010-11-02 | 2013-05-21 | Albert L Coles, Jr. | Systems and methods for producing organic cannabis tincture |
| EP2654864B1 (en) | 2010-12-22 | 2020-10-28 | Syqe Medical Ltd. | System for drug delivery |
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| JP6562912B2 (ja) * | 2013-06-26 | 2019-08-21 | アムジェン インコーポレイテッド | Ｃｂ１受容体抗原結合タンパク質及びその使用 |
| ES2610988T3 (es) | 2013-10-29 | 2017-05-04 | Echo Pharmaceuticals B.V. | Comprimido que contiene cannabidiol, método para su producción y uso de tal comprimido en el tratamiento oral de trastornos psicóticos o de ansiedad |
| AU2014340710B2 (en) | 2013-10-29 | 2019-08-22 | Echo Pharmaceuticals B.V. | Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
| JP6980388B2 (ja) | 2014-06-30 | 2021-12-15 | サイケ メディカル リミテッドSyqe Medical Ltd. | 気流調節吸入装置 |
| US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
| EP3539599B1 (en) | 2014-06-30 | 2021-10-20 | Syqe Medical Ltd. | Drug dose cartridge for an inhaler device |
| IL294077A (en) | 2014-06-30 | 2022-08-01 | Syqe Medical Ltd | Method and device for vaporizing and inhaling substances |
| JP6747988B2 (ja) * | 2014-06-30 | 2020-08-26 | サイケ メディカル リミテッドＳｙｑｅ Ｍｅｄｉｃａｌ Ｌｔｄ． | 活性薬剤肺送達のための方法、装置及びシステム |
| IL273507B2 (en) | 2014-06-30 | 2024-06-01 | Syqe Medical Ltd | Methods, devices and systems for administering active substances through the lungs |
| EP3160565B1 (en) | 2014-06-30 | 2021-08-18 | Syqe Medical Ltd. | Devices and systems for pulmonary delivery of active agents |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| US9539295B2 (en) | 2014-12-05 | 2017-01-10 | Bradley Michael Bohus | Cannabidiol (CBD) enriched alcohol |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
| GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2542155B (en) | 2015-09-09 | 2018-08-01 | Gw Pharma Ltd | Use of cannabidiol in the treatment of mental disorders |
| CN108883399B (zh) | 2015-12-22 | 2021-06-22 | 周格尼克斯国际有限公司 | 芬氟拉明组合物及其制备方法 |
| US20170174614A1 (en) | 2015-12-22 | 2017-06-22 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| WO2017118980A1 (en) | 2016-01-06 | 2017-07-13 | Syqe Medical Ltd. | Low dose therapeutic treatment |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
| AU2017290107A1 (en) | 2016-06-29 | 2019-01-17 | CannScience Innovations Inc. | Decarboxylated cannabis resins, uses thereof and methods of making same |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| US20210069170A1 (en) | 2016-07-23 | 2021-03-11 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
| US11701348B1 (en) | 2016-07-23 | 2023-07-18 | Turtle Bear Holdings, Llc | Psilocybin compositions |
| RU2021106383A (ru) * | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| US10835501B2 (en) | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
| CN108078984B (zh) * | 2016-11-23 | 2020-11-20 | 汉义生物科技（北京）有限公司 | 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用 |
| CN108143726B (zh) * | 2016-12-02 | 2020-05-08 | 汉义生物科技（北京）有限公司 | 大麻二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途 |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| WO2018115001A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| RU2764443C2 (ru) | 2016-12-20 | 2022-01-17 | Лтс Ломанн Терапи-Систем Аг | Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен |
| EP3579832A4 (en) * | 2017-02-09 | 2020-12-30 | Caamtech, LLC | COMPOSITIONS AND PROCESSES INCLUDING A PSILOCYBIN DERIVATIVE |
| US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
| US12414936B2 (en) | 2017-02-09 | 2025-09-16 | Caamtech, Inc. | Compositions comprising a serotonergic tryptamine compound |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2560019A (en) | 2017-02-27 | 2018-08-29 | Gw Res Ltd | Use of cannabinoids in the treatment of leukaemia |
| GB2564383B (en) | 2017-06-23 | 2021-04-21 | Gw Res Ltd | Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex |
| CN110799180A (zh) | 2017-06-26 | 2020-02-14 | 罗曼治疗系统股份公司 | 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统 |
| CN107469087A (zh) * | 2017-09-10 | 2017-12-15 | 孙永丽 | 用于治疗精神病的制剂 |
| US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| WO2019099745A1 (en) * | 2017-11-16 | 2019-05-23 | CaaMTech, LLC | Compositions comprising a psilocybin derivative and a cannabinoid |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| WO2019113079A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| CA3091776C (en) * | 2018-02-20 | 2021-12-28 | Supera Pharmaceuticals, Inc. | Genetically modified cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders |
| WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| AU2019291060B2 (en) | 2018-06-20 | 2024-09-05 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| US12144787B2 (en) | 2018-11-19 | 2024-11-19 | Zogenix International Limited | Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5) |
| WO2020188569A1 (en) * | 2019-03-20 | 2020-09-24 | Bol Pharma Ltd. | Methods and compositions for preventing or treating weight gain caused by psychiatric drugs |
| SG11202113266YA (en) | 2019-06-04 | 2021-12-30 | Sunovion Pharmaceuticals Inc | Modified release formulations and uses thereof |
| GB201910389D0 (en) | 2019-07-19 | 2019-09-04 | Gw Pharma Ltd | Novel compounds, methods for their manufacture, and uses thereof |
| GB2588576A (en) | 2019-08-27 | 2021-05-05 | Gw Res Ltd | Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease |
| CA3158059A1 (en) | 2019-11-19 | 2021-05-27 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
| GB201916849D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916846D0 (en) | 2019-11-19 | 2020-01-01 | Gw Res Ltd | Cannabidiol-type cannabinoid compound |
| GB201916974D0 (en) | 2019-11-21 | 2020-01-08 | Gw Res Ltd | Cannabidol-type cannabinoid compound |
| GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| CA3187303A1 (en) | 2020-07-28 | 2022-02-03 | Impello Biosciences, Inc. | Methods and compositions for altering secondary metabolites in plants |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| US20240009133A1 (en) * | 2020-11-16 | 2024-01-11 | Orcosa Inc. | Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs |
| US11337934B1 (en) | 2021-04-08 | 2022-05-24 | Lanny Leo Johnson | Compositions including a cannabinoid and protocatechuic acid |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| IL136839A (en) * | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
| US7053092B2 (en) * | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
| DE60202270T2 (de) * | 2001-03-22 | 2005-05-19 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazolderivate mit cb1-antagonistischer wirkung |
| MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
| US20050154202A1 (en) * | 2002-04-05 | 2005-07-14 | Hagmann William K. | Substituted aryl amides |
| DE10226494A1 (de) * | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
| GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
| GB0222077D0 (en) * | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
| CN1989968B (zh) | 2002-12-27 | 2011-05-11 | 大塚制药株式会社 | 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂 |
| MXPA05012538A (es) * | 2003-05-23 | 2006-02-22 | Otsuka Pharma Co Ltd | Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo. |
| US8470874B2 (en) | 2003-06-24 | 2013-06-25 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabichromene type compounds |
| RU2006110545A (ru) * | 2003-09-02 | 2007-10-10 | Зольвай Фармасьютикалз Гмбх (De) | Новое медицинское применение избирательных антагонистов св1-рецептора |
| AU2004273865A1 (en) * | 2003-09-18 | 2005-03-31 | Merck & Co., Inc. | Substituted sulfonamides |
| AR045651A1 (es) * | 2003-09-19 | 2005-11-02 | Solvay Pharm Bv | Derivados de tiazol como moduladores del receptor de cannabinoide |
| AU2004309365A1 (en) * | 2003-12-19 | 2005-07-14 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
| WO2006017892A1 (en) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
| GB0425248D0 (en) * | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
| US9168278B2 (en) * | 2004-11-16 | 2015-10-27 | Gw Pharma Limited | Use for cannabinoid |
| FR2882931B1 (fr) * | 2005-03-14 | 2007-05-18 | Sanofi Aventis Sa | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique |
| PE20071092A1 (es) | 2005-12-08 | 2007-12-10 | Aventis Pharma Inc | Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico |
| WO2007136571A1 (en) * | 2006-05-15 | 2007-11-29 | Merck & Co., Inc. | Pro-drugs of tertiary alcohols |
| GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
| EP1867308B1 (en) | 2006-06-12 | 2010-10-20 | Camp Scandinavia Ab | Frame for a hyperextension brace |
| US8481085B2 (en) | 2006-06-15 | 2013-07-09 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabigerol |
| GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| WO2008133884A2 (en) * | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| US8889076B2 (en) * | 2008-12-29 | 2014-11-18 | Uop Llc | Fluid catalytic cracking system and process |
-
2008
- 2008-01-04 GB GB0800390A patent/GB2456183A/en not_active Withdrawn
- 2008-12-17 EP EP16167562.4A patent/EP3095452B1/en active Active
- 2008-12-17 ES ES16167562T patent/ES2750728T3/es active Active
- 2008-12-17 PT PT161675624T patent/PT3095452T/pt unknown
- 2008-12-17 JP JP2010541094A patent/JP5409650B2/ja active Active
- 2008-12-17 KR KR1020107017111A patent/KR101631518B1/ko active Active
- 2008-12-17 BR BRPI0821461A patent/BRPI0821461A8/pt not_active IP Right Cessation
- 2008-12-17 RU RU2010132649/15A patent/RU2503448C2/ru active
- 2008-12-17 HU HUE13152600A patent/HUE047214T2/hu unknown
- 2008-12-17 PL PL13152600T patent/PL2609928T3/pl unknown
- 2008-12-17 PL PL16167562T patent/PL3095452T3/pl unknown
- 2008-12-17 WO PCT/GB2008/004217 patent/WO2009087351A1/en not_active Ceased
- 2008-12-17 PT PT131526006T patent/PT2609928T/pt unknown
- 2008-12-17 AU AU2008346285A patent/AU2008346285B2/en active Active
- 2008-12-17 MX MX2010007073A patent/MX2010007073A/es active IP Right Grant
- 2008-12-17 EP EP13152600.6A patent/EP2609928B1/en active Active
- 2008-12-17 CN CN200880125822.5A patent/CN101939017B/zh active Active
- 2008-12-17 ES ES13152600T patent/ES2751117T3/es active Active
- 2008-12-17 UA UAA201009705A patent/UA103472C2/uk unknown
- 2008-12-17 CA CA2708921A patent/CA2708921C/en active Active
- 2008-12-17 NZ NZ586648A patent/NZ586648A/xx unknown
- 2008-12-17 GB GB1012953.4A patent/GB2468828B/en active Active
- 2008-12-17 ES ES08869534.1T patent/ES2574155T3/es active Active
- 2008-12-17 EP EP08869534.1A patent/EP2249848B1/en active Active
- 2008-12-17 US US12/811,393 patent/US9017737B2/en active Active
- 2008-12-17 HU HUE16167562A patent/HUE046780T2/hu unknown
- 2008-12-24 CL CL2008003902A patent/CL2008003902A1/es unknown
- 2008-12-29 AR ARP080105764A patent/AR070063A1/es unknown
- 2008-12-31 TW TW097151656A patent/TWI519299B/zh not_active IP Right Cessation
- 2008-12-31 TW TW103121762A patent/TW201436791A/zh unknown
-
2009
- 2009-01-05 PE PE2014000565A patent/PE20141249A1/es not_active Application Discontinuation
- 2009-01-05 PE PE2009000002A patent/PE20091361A1/es not_active Application Discontinuation
-
2010
- 2010-07-04 IL IL206784A patent/IL206784A0/en active IP Right Grant
- 2010-07-29 ZA ZA2010/05443A patent/ZA201005443B/en unknown
- 2010-08-04 CO CO10095174A patent/CO6290695A2/es not_active Application Discontinuation
-
2012
- 2012-09-21 GB GBGB1216932.2A patent/GB201216932D0/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011508765A5 (cg-RX-API-DMAC7.html) | ||
| RU2010132649A (ru) | Применение каннабиноидов в комбинации с антипсихотическим лекарственным средством | |
| CA3018635C (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| BRPI0507609A (pt) | combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| JP2014517050A5 (cg-RX-API-DMAC7.html) | ||
| RU2014101482A (ru) | Способ применения 4-((1r,3s)-6-хлор-3-фенилиндан-1-ил)-1,2,2-триметилпиперазина и его солей в лечении шизофрении | |
| JP2015524444A5 (cg-RX-API-DMAC7.html) | ||
| RU2014122858A (ru) | Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил)бензо[в]тиофен-2-карбосамидом и его фармацевтически приемлемыми солями | |
| ES2750662T3 (es) | Orvepitant para el tratamiento del prurito crónico | |
| JP2012524112A5 (cg-RX-API-DMAC7.html) | ||
| HRP20192189T1 (hr) | Doziranja i terapijske primjene l-4-klorokinurenina | |
| JP2014533729A (ja) | ケルセチンを含有するｃ型肝炎ウイルスの感染を治療するための医薬品 | |
| ES2705726T3 (es) | Métodos para tratar el aumento de peso inducido por antipsicóticos | |
| FI3970707T3 (fi) | Kannabidivariinin käyttö skitsofrenian negatiivisten oireiden hoitoon | |
| AR076175A1 (es) | Combinaciones para el tratamiento de enfermedades respiratorias. | |
| EA201070557A1 (ru) | Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов | |
| JP2009534367A (ja) | 前駆症状症候群の治療にｍ１／ｍ４ムスカリン性アゴニスト（サブコメリン）を用いる単独及び組合せ療法 | |
| BR112015002726A8 (pt) | combinação, composição farmacêutica, kit, e, usos de uma combinação, e de uma composição farmaceutica | |
| PH12014501601A1 (en) | Artemisinin-based combination therapy for treating viral mediated disease | |
| WO2023214391A1 (en) | Method for treating cancers and neurological diseases using quercetin-containing compositions | |
| RU2014133544A (ru) | Терапевтические применения | |
| JP2014037445A (ja) | 抵抗性統合失調症およびその他のｃｎｓ疾患の治療 | |
| Cordeiro et al. | Pisa syndrome induced by rapid increase and high dosage of risperidone | |
| Tablets | Full Prescribing Information |